FLAG Assay As a Novel Method for Real-time Signal Generation During PCR: Application to Detection and Genotyping of KRAS Codon 12 Mutations

Overview

Journal Nucleic Acids Res

Publisher Oxford University Press

Specialty Biochemistry

Date 2007 Oct 13

PMID 17932053

Citations 25

Authors

Giulia Amicarelli

Erlet Shehi

G Mike Makrigiorgos

Daniel Adlerstein

Affiliations

Soon will be listed here.

Abstract

Real-time signal generation methods for detection and characterization of low-abundance mutations in genomic DNA are powerful tools for cancer diagnosis and prognosis. Mutations in codon 12 of the oncogene KRAS, for example, are frequently found in several types of human cancers. We have developed a novel real-time PCR technology, FLAG (FLuorescent Amplicon Generation) and adapted it for simultaneously (i) amplifying mutated codon 12 KRAS sequences, (ii) monitoring in real-time the amplification and (iii) genotyping the exact nucleotide alteration. FLAG utilizes the exceptionally thermostable endonuclease PspGI for real-time signal generation by cleavage of quenched fluorophores from the 5'-end of the PCR products and, concurrently, for selecting KRAS mutations over wild type. By including peptide-nucleic-acid probes in the reaction, simultaneous genotyping is achieved that circumvents the requirement for sequencing. FLAG enables high-throughput, closed-tube KRAS mutation detection down to approximately 0.1% mutant-to-wild type. The assay was validated on model systems and compared with allele-specific PCR sequencing for screening 27 cancer specimens. Diverse applications of FLAG for real-time PCR or genotyping applications in cancer, virology or infectious diseases are envisioned.

Citing Articles

Pyrimidine-Dependent UV-Mediated Cross-Linking Magnifies Minor Genetic or Epigenetic Changes in Clinical Samples.

Yu F, Ahmed F, Smilkou S, Yasmin-Karim S, Darbeheshti F, Markou A Clin Chem. 2024; 70(9):1151-1161.

PMID: 39039866 PMC: 11371481. DOI: 10.1093/clinchem/hvae086.

Enzymatic Methods for Mutation Detection in Cancer Samples and Liquid Biopsies.

Darbeheshti F, Makrigiorgos G Int J Mol Sci. 2023; 24(2).

PMID: 36674433 PMC: 9865676. DOI: 10.3390/ijms24020923.

Pre-PCR Mutation-Enrichment Methods for Liquid Biopsy Applications.

Darbeheshti F, Yu F, Makrigiorgos G Cancers (Basel). 2022; 14(13).

PMID: 35804916 PMC: 9264780. DOI: 10.3390/cancers14133143.

Nuclease-Assisted, Multiplexed Minor-Allele Enrichment: Application in Liquid Biopsy of Cancer.

Yu F, Leong K, Makrigiorgos G Methods Mol Biol. 2022; 2394:433-451.

PMID: 35094339 DOI: 10.1007/978-1-0716-1811-0_22.

Untangling the KRAS mutated lung cancer subsets and its therapeutic implications.

Ritu K, Kumar P, Singh A, Nupur K, Spalgias S, Mrigpuri P Mol Biomed. 2021; 2(1):40.

PMID: 34918209 PMC: 8677854. DOI: 10.1186/s43556-021-00061-0.

References

Le Calvez F, Mukeria A, Hunt J, Kelm O, Hung R, Taniere P . TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. Cancer Res. 2005; 65(12):5076-83. DOI: 10.1158/0008-5472.CAN-05-0551. View

Leon S, Shapiro B, SKLAROFF D, Yaros M . Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977; 37(3):646-50. View

Syvanen A, Aalto-Setala K, Harju L, Kontula K, Soderlund H . A primer-guided nucleotide incorporation assay in the genotyping of apolipoprotein E. Genomics. 1990; 8(4):684-92. DOI: 10.1016/0888-7543(90)90255-s. View

Nauck M, Wieland H, Marz W . Rapid, homogeneous genotyping of the 4G/5G polymorphism in the promoter region of the PAII gene by fluorescence resonance energy transfer and probe melting curves. Clin Chem. 1999; 45(8 Pt 1):1141-7. View

Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais M . Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer. 2007; 96(8):1166-9. PMC: 2360149. DOI: 10.1038/sj.bjc.6603685. View

El Housni H, Heimann P, Parma J, Vassart G . Single-nucleotide polymorphism genotyping by melting analysis of dual-labeled probes: examples using factor V Leiden and prothrombin 20210A mutations. Clin Chem. 2003; 49(10):1669-72. DOI: 10.1373/49.10.1669. View

Peirson S, Butler J . Quantitative polymerase chain reaction. Methods Mol Biol. 2007; 362:349-62. DOI: 10.1007/978-1-59745-257-1_25. View

Newton C, Graham A, Heptinstall L, Powell S, Summers C, Kalsheker N . Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res. 1989; 17(7):2503-16. PMC: 317639. DOI: 10.1093/nar/17.7.2503. View

Hilbe W, Dlaska M, Duba H, Dirnhofer S, Eisterer W, Oberwasserlechner F . Automated real-time PCR to determine K-ras codon 12 mutations in non-small cell lung cancer: comparison with immunohistochemistry and clinico-pathological features. Int J Oncol. 2003; 23(4):1121-6. View

10.

WARD R, Hawkins N, Ogrady R, Sheehan C, OConnor T, Impey H . Restriction endonuclease-mediated selective polymerase chain reaction: a novel assay for the detection of K-ras mutations in clinical samples. Am J Pathol. 1998; 153(2):373-9. PMC: 1852993. DOI: 10.1016/S0002-9440(10)65581-2. View

11.

Li J, Harris L, Mamon H, Kulke M, Liu W, Zhu P . Whole genome amplification of plasma-circulating DNA enables expanded screening for allelic imbalance in plasma. J Mol Diagn. 2006; 8(1):22-30. PMC: 1867563. DOI: 10.2353/jmoldx.2006.050074. View

12.

Thiede C, Bayerdorffer E, Blasczyk R, Wittig B, Neubauer A . Simple and sensitive detection of mutations in the ras proto-oncogenes using PNA-mediated PCR clamping. Nucleic Acids Res. 1996; 24(5):983-4. PMC: 145732. DOI: 10.1093/nar/24.5.983. View

13.

Amicarelli G, Adlerstein D, Shehi E, Wang F, Makrigiorgos G . Genotype-specific signal generation based on digestion of 3-way DNA junctions: application to KRAS variation detection. Clin Chem. 2006; 52(10):1855-63. DOI: 10.1373/clinchem.2006.068817. View

14.

Thelwell N, Millington S, Solinas A, Booth J, Brown T . Mode of action and application of Scorpion primers to mutation detection. Nucleic Acids Res. 2000; 28(19):3752-61. PMC: 110766. DOI: 10.1093/nar/28.19.3752. View

15.

Kopreski M, Benko F, Borys D, Khan A, McGarrity T, Gocke C . Somatic mutation screening: identification of individuals harboring K-ras mutations with the use of plasma DNA. J Natl Cancer Inst. 2000; 92(11):918-23. DOI: 10.1093/jnci/92.11.918. View

16.

Luo J, Chan E, Shih C, Chen T, Liang Y, Hwang T . Detection of rare mutant K-ras DNA in a single-tube reaction using peptide nucleic acid as both PCR clamp and sensor probe. Nucleic Acids Res. 2006; 34(2):e12. PMC: 1345699. DOI: 10.1093/nar/gnj008. View

17.

Kwiatkowski R, Lyamichev V, de Arruda M, Neri B . Clinical, genetic, and pharmacogenetic applications of the Invader assay. Mol Diagn. 2000; 4(4):353-64. DOI: 10.1016/s1084-8592(99)80012-5. View

18.

Ehrich M, Bocker S, Van Den Boom D . Multiplexed discovery of sequence polymorphisms using base-specific cleavage and MALDI-TOF MS. Nucleic Acids Res. 2005; 33(4):e38. PMC: 549577. DOI: 10.1093/nar/gni038. View

19.

Pingoud V, Conzelmann C, Kinzebach S, Sudina A, Metelev V, Kubareva E . PspGI, a type II restriction endonuclease from the extreme thermophile Pyrococcus sp.: structural and functional studies to investigate an evolutionary relationship with several mesophilic restriction enzymes. J Mol Biol. 2003; 329(5):913-29. DOI: 10.1016/s0022-2836(03)00523-0. View

20.

Morgan R, Xiao J, Xu S . Characterization of an extremely thermostable restriction enzyme, PspGI, from a Pyrococcus strain and cloning of the PspGI restriction-modification system in Escherichia coli. Appl Environ Microbiol. 1998; 64(10):3669-73. PMC: 106503. DOI: 10.1128/AEM.64.10.3669-3673.1998. View